

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 27, 2003

-----  
(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

-----  
(Address of principal executive offices)

336-229-1127

-----  
(Registrant's telephone number, including area code)

ITEM 9. Regulation FD Disclosure

On October 27, 2003, Laboratory Corporation of America -Registered Trademark-  
Holdings (LabCorp -Registered Trademark-) (NYSE:LH) announced the appointment  
of Paul R. Billings, MD, PhD, FACP, FACMG, as Vice President National Director  
of Genetics and Genomics. Dr. Billings will be responsible for all new and  
current genetic and genomic related tests and services at LabCorp.

Exhibits:

99.1 Press release of the Company dated October 27, 2003.

SIGNATURES

Pursuant to the requirements of the Securities and  
Exchange Act of 1934, the registrant has duly caused  
this report to be signed on its behalf by the  
undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Registrant)

By:/s/ BRADFORD T. SMITH

-----  
Bradford T. Smith  
Executive Vice President  
and Secretary

Date: October 27, 2003

Laboratory Corporation of America-Registered Trademark- Holdings  
358 South Main Street  
Burlington, North Carolina 27215  
Telephone: 336-584-5171

For Immediate Release:

Contact: Pamela Sherry - (336) 436-4855  
Shareholder Direct: (800) LAB-0401  
Company Information: [www.LabCorp.com](http://www.LabCorp.com)

LabCorp-Registered Trademark- Names Paul R. Billings, MD, PhD as  
Vice President National Director of Genetics and Genomics

Burlington, NC, October 27, 2003-Laboratory Corporation of America-  
Registered Trademark- Holdings (LabCorp-Registered Trademark-) (NYSE:LH)  
announced today the appointment of Paul R. Billings, MD, PhD, FACP, FACMG,  
as Vice President National Director of Genetics and Genomics. Dr. Billings  
will be responsible for all new and current genetic and genomic related  
tests and services at LabCorp.

Dr. Billings is an internationally recognized authority on genetic testing  
and has published more than 130 scholarly articles in such publications as  
Journal of Experimental Medicine, Proceedings of the National Academy of  
Science, and the New England Journal of Medicine, and book chapters in  
addition to his book, DNA on Trial: Genetic Identification and Criminal  
Justice. He was also on the joint NIH/DOE (National Institutes of  
Health/U.S. Department of Energy) Task Force on Genetic Information and  
Insurance and has testified on many occasions to the United States Congress  
and to state legislatures on issues involving human genetics. His works and  
comments have appeared in such popular media outlets as the New York Times,  
Boston Globe, Wired and Los Angeles Times.

Prior to joining LabCorp, Dr. Billings was a Vice President for Life  
Sciences and Clinical Affairs for WIPRO, Ltd., via its subsidiary WIPRO  
HealthSciences. He has also recently acted as Executive Vice President  
and Chief Scientific and Medical Officer of Genesage, Inc. and as the  
Editor-In-Chief of GeneSage's flagship publication, GeneLetter. In  
addition, Dr. Billings is an Adjunct Professor in the Department of  
Anthropology at the University of California at Berkeley and Principal  
Investigator on a Robert Wood Johnson Foundation funded project studying  
legal and policy precedents in genomic medicine with the Council for  
Responsible Genetics.

"It is with great pleasure that I welcome Dr. Paul Billings to LabCorp,"  
said Myla P. Lai-Goldman, MD, LabCorp executive vice president, chief  
scientific officer and medical director. "In addition to being a world  
renowned geneticist, Dr. Billings brings to LabCorp his expertise in  
clinical genetics and the genetics of common disease. Under Dr. Billings'  
direction, LabCorp will expand its already advanced genomic testing  
capabilities."

Dr. Billings' clinical activities have included: clinical faculty  
appointments at Harvard Medical School, the University of California at San  
Francisco, and Stanford University. He has also served as Chief of Division  
of Genetic Medicine and Vice-Chairman of the Department of Medicine at  
California Pacific Medical Center in San Francisco, California.

Dr. Billings received his MD and PhD degrees from Harvard University in  
1979 and completed his clinical training in Internal Medicine and Medical  
Genetics at the University of Washington in Seattle in 1984. He is a  
Founding Fellow of the American College of Medical Genetics, a Fellow of  
the American College of Physicians and has been a distinguished lecturer  
for the national science society, Sigma Xi.

About LabCorp:

Laboratory Corporation of America-Registered Trademark- Holdings is a  
pioneer in commercializing new diagnostic technologies and the first in its  
industry to embrace genomic testing. With annual revenues of \$2.5 billion  
in 2002, over 24,000 employees nationwide, and more than 200,000 clients,  
LabCorp offers over 4,000 clinical assays ranging from blood analyses to  
HIV and genomic testing. LabCorp combines its expertise in innovative  
clinical testing technology with its Centers of Excellence: The Center for  
Molecular Biology and Pathology, in Research Triangle Park, NC; National  
Genetics Institute, Inc. in Los Angeles, CA; ViroMed Laboratories, Inc.  
based in Minneapolis, MN; The Center for Esoteric Testing in Burlington,  
NC; and DIANON Systems, Inc. based in Stratford, CT. LabCorp clients  
include physicians, government agencies, managed care organizations,  
hospitals, clinical labs, and pharmaceutical companies. To learn more about  
our growing organization, visit our web site at: [www.LabCorp.com](http://www.LabCorp.com).  
Each of the above forward-looking statements is subject to change based on

various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2002 and subsequent SEC filings.